Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2018

1.

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.

Cortes J, Schöffski P, Littlefield BA.

Cancer Treat Rev. 2018 Aug 21;70:190-198. doi: 10.1016/j.ctrv.2018.08.008. [Epub ahead of print] Review.

PMID:
30243063
2.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J.

Eur J Cancer. 2018 Sep 18;103:147-154. doi: 10.1016/j.ejca.2018.08.002. [Epub ahead of print]

PMID:
30241001
3.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392. [Epub ahead of print]

PMID:
30235087
4.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.

Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, Medeiros BC, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons BP, Riehl T, Colburn D.

Br J Haematol. 2018 Sep 11. doi: 10.1111/bjh.15571. [Epub ahead of print] No abstract available.

PMID:
30203489
5.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.

6.

A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Sep 5. pii: blood-2018-04-846626. doi: 10.1182/blood-2018-04-846626. [Epub ahead of print]

PMID:
30185431
7.

DUSP5 expression associates with poor prognosis in human neuroblastoma.

Aurtenetxe O, Zaldumbide L, Erramuzpe A, López R, López JI, Cortés JM, Pulido R, Nunes-Xavier CE.

Exp Mol Pathol. 2018 Aug 29. pii: S0014-4800(18)30236-3. doi: 10.1016/j.yexmp.2018.08.008. [Epub ahead of print]

PMID:
30171833
8.

Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient.

Lewis TC, Cortes J, Altshuler D, Papadopoulos J.

J Intensive Care Med. 2018 Aug 30:885066618796486. doi: 10.1177/0885066618796486. [Epub ahead of print]

PMID:
30165770
9.

Acute respiratory syndrome following accidental inhalation of mercury vapor.

Cortes J, Peralta J, Díaz-Navarro R.

Clin Case Rep. 2018 Jun 21;6(8):1535-1537. doi: 10.1002/ccr3.1656. eCollection 2018 Aug.

10.

Extracellular HMGA1 promotes tumor Invasion and Metastasis in Triple-Negative Breast Cancer.

Mendez O, Peg V, Salvans C, Pujals M, Fernandez Y, Abasolo I, Perez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S, Ramon Y Cajal S, Tabernero J, Cortes J, Arribas J, Villanueva J.

Clin Cancer Res. 2018 Aug 22. pii: clincanres.0517.2018. doi: 10.1158/1078-0432.CCR-18-0517. [Epub ahead of print]

PMID:
30135148
11.

Is there a role for immunotherapy in HER2-positive breast cancer?

Holgado E, Perez-Garcia J, Gion M, Cortes J.

NPJ Breast Cancer. 2018 Aug 15;4:21. doi: 10.1038/s41523-018-0072-8. eCollection 2018. Review.

12.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H.

Lancet Haematol. 2018 Sep;5(9):e411-e421. doi: 10.1016/S2352-3026(18)30132-7. Epub 2018 Aug 13.

PMID:
30115541
13.

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.

Haematologica. 2018 Aug 9. pii: haematol.2018.188987. doi: 10.3324/haematol.2018.188987. [Epub ahead of print]

14.

Acute myeloid leukaemia.

Short NJ, Rytting ME, Cortes JE.

Lancet. 2018 Aug 18;392(10147):593-606. doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2. Review.

PMID:
30078459
15.

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.

Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G.

Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25240. [Epub ahead of print] No abstract available.

PMID:
30074261
16.

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.

Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA.

Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25238. [Epub ahead of print]

PMID:
30074259
17.

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM.

Acta Haematol. 2018;140(1):30-39. doi: 10.1159/000490092. Epub 2018 Aug 2.

18.

Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.

Sharma P, López-Tarruella S, Garcia-Saenz JA, Khan QJ, Gomez H, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Marquez-Rodas I, Perou CM, Lehn C, Wang YY, Klemp JR, Mammen JM, Wagner J, Amin A, O'Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M.

Clin Cancer Res. 2018 Jul 30. pii: clincanres.0585.2018. doi: 10.1158/1078-0432.CCR-18-0585. [Epub ahead of print]

PMID:
30061361
19.
20.

Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?

Rubio IT, Wyld L, Cardoso F, Curigliano G, Kovacs T, Poortmans P, Cortes J.

Breast. 2018 Oct;41:133-135. doi: 10.1016/j.breast.2018.07.008. Epub 2018 Jul 23.

PMID:
30056250
21.

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available.

PMID:
30032243
22.

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.

Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F.

Am J Hematol. 2018 Jul 20. doi: 10.1002/ajh.25198. [Epub ahead of print]

PMID:
30028037
23.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.

24.

Structure-function multi-scale connectomics reveals a major role of the fronto-striato-thalamic circuit in brain aging.

Bonifazi P, Erramuzpe A, Diez I, Gabilondo I, Boisgontier MP, Pauwels L, Stramaglia S, Swinnen SP, Cortes JM.

Hum Brain Mapp. 2018 Jul 13. doi: 10.1002/hbm.24312. [Epub ahead of print]

PMID:
30004604
25.

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.

Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA.

Nat Commun. 2018 Jul 10;9(1):2670. doi: 10.1038/s41467-018-04924-z.

26.

Crystal and melt inclusion timescales reveal the evolution of magma migration before eruption.

Ruth DCS, Costa F, Bouvet de Maisonneuve C, Franco L, Cortés JA, Calder ES.

Nat Commun. 2018 Jul 9;9(1):2657. doi: 10.1038/s41467-018-05086-8.

27.

Gene expression changes by high-polyphenols cocoa powder intake: a randomized crossover clinical study.

Barrera-Reyes PK, Hernández-Ramírez N, Cortés J, Poquet L, Redeuil K, Rangel-Escareño C, Kussmann M, Silva-Zolezzi I, Tejero ME.

Eur J Nutr. 2018 Jun 8. doi: 10.1007/s00394-018-1736-8. [Epub ahead of print]

PMID:
29948216
28.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jun 18. doi: 10.1007/s12094-018-1909-1. [Epub ahead of print]

PMID:
29916189
29.

Enhanced prefrontal functional-structural networks to support postural control deficits after traumatic brain injury in a pediatric population.

Diez I, Drijkoningen D, Stramaglia S, Bonifazi P, Marinazzo D, Gooijers J, Swinnen SP, Cortes JM.

Netw Neurosci. 2017 Jun 1;1(2):116-142. doi: 10.1162/NETN_a_00007. eCollection 2017 Spring.

30.

Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.

López JI, Pulido R, Cortés JM, Angulo JC, Lawrie CH.

Pathol Res Pract. 2018 Aug;214(8):1110-1114. doi: 10.1016/j.prp.2018.06.003. Epub 2018 Jun 12.

PMID:
29910061
31.

Introduction to a review series on adolescent and young adult malignant hematology.

Cortes J.

Blood. 2018 Jul 26;132(4):345-346. doi: 10.1182/blood-2018-05-846105. Epub 2018 Jun 12. No abstract available.

PMID:
29895663
32.

Conformational changes in antibody Fab fragments upon binding and their consequences on the performance of docking algorithms.

Barozet A, Bianciotto M, Siméon T, Minoux H, Cortés J.

Immunol Lett. 2018 Aug;200:5-15. doi: 10.1016/j.imlet.2018.06.002. Epub 2018 Jun 6.

PMID:
29885326
33.

Response kinetics and factors predicting survival in core-binding factor leukemia.

Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur G.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0158-1. [Epub ahead of print] No abstract available.

PMID:
29884905
34.

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, Kumarakulasinghe NB, Richard JLC, Bin Adam Isa ZF, Pang B, Guzman M, Siqin Z, Yang H, Tam WL, Serra V, Eichhorn PJA.

J Exp Med. 2018 Jul 2;215(7):1913-1928. doi: 10.1084/jem.20171960. Epub 2018 Jun 7.

35.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.

Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators.

Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.

36.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

37.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
38.

Reply to K.S. Shohdy et al.

Traina TA, Cortes J.

J Clin Oncol. 2018 Aug 10;36(23):2458-2459. doi: 10.1200/JCO.2018.78.8349. Epub 2018 May 30. No abstract available.

PMID:
29847296
39.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 May 24. pii: haematol.2018.191361. doi: 10.3324/haematol.2018.191361. [Epub ahead of print] No abstract available.

40.

Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.

Gomez-Lumbreras A, Cortes J, Giner-Soriano M, Quijada-Manuitt MA, Morros R.

J Cardiovasc Pharmacol Ther. 2018 Jan 1:1074248418778544. doi: 10.1177/1074248418778544. [Epub ahead of print]

PMID:
29792125
41.

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 May 18. doi: 10.1093/jnci/djy076. [Epub ahead of print]

PMID:
29788230
42.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 Aug;103(8):1298-1307. doi: 10.3324/haematol.2017.171249. Epub 2018 May 17.

43.

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E.

Br J Cancer. 2018 May 16. doi: 10.1038/s41416-018-0082-1. [Epub ahead of print]

44.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.

Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041. eCollection 2018 Apr 17.

45.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158. [Epub ahead of print]

PMID:
29741984
46.

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2018 Jul 1;124(13):2740-2747. doi: 10.1002/cncr.31357. Epub 2018 May 3.

PMID:
29723397
47.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2018 Apr 30. doi: 10.1093/annonc/mdx804. [Epub ahead of print] No abstract available.

PMID:
29718117
48.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
49.

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.

Cortes J, Pérez-García J, Whiting S, Wan Y, Solem C, Tai MH, Margunato-Debay S, Ko A, Fandi A, Botteman M.

Clin Breast Cancer. 2018 Mar 30. pii: S1526-8209(17)30778-4. doi: 10.1016/j.clbc.2018.03.014. [Epub ahead of print]

50.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K.

J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.

PMID:
29702001

Supplemental Content

Loading ...
Support Center